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Abstract
Background: Cyclooxygenase (COX)-2, the inducible isoform of prostaglandin (PG) synthase, has been implicated
in tumor metastasis. Interaction of COX-2 with its specific EP receptors on the surface of cancer cells has been
reported to induce cancer invasion. However, the effects of COX-2 on migration activity in human chondrosarcoma
cells are mostly unknown. In this study, we examined whether COX-2 and EP interaction are involved in metastasis
of human chondrosarcoma.
Results: We found that over-expression of COX-2 or exogenous PGE2 increased the migration of human
chondrosarcoma cells. We also found that human chondrosarcoma tissues and chondrosarcoma cell lines had
significant expression of the COX-2 which was higher than that in normal cartilage. By using pharmacological
inhibitors or activators or genetic inhibition by the EP receptors, we discovered that the EP1 receptor but not other
PGE receptors is involved in PGE2-mediated cell migration and a2b1 integrin expression. Furthermore, we found
that human chondrosarcoma tissues expressed a higher level of EP1 receptor than normal cartilage. PGE2-mediated
migration and integrin up-regulation were attenuated by phospholipase C (PLC), protein kinase C (PKC) and c-Src
inhibitor. Activation of the PLCb, PKCa, c-Src and NF-B signaling pathway after PGE2 treatment was demonstrated,
and PGE2-induced expression of integrin and migration activity were inhibited by the specific inhibitor, siRNA and
mutants of PLC, PKC, c-Src and NF-B cascades.
Conclusions: Our results indicated that PGE2 enhances the migration of chondrosarcoma cells by increasing a2b1
integrin expression through the EP1/PLC/PKCa/c-Src/NF-B signal transduction pathway.
Background
Chondrosarcoma is the second most common malig-
nancy of bone and it has a poor response to chemother-
apy or radiation treatment currently-used, making the
management of chondrosarcomas a complicated chal-
lenge [1]. Clinically, surgical resection remains the pri-
mary mode of therapy for chondrosarcoma. In the
absence of an effective adjuvant therapy, this mesenchy-
mal malignancy has a poor prognosis and therefore, it is
important to explore novel and adequate remedies [2].
Since chondrosarcoma is a type of highly malignant
tumor with a potent capacity to invade locally and
metastasize distantly [2], an approach that decreases its
ability to invade and metastasize may facilitate the
development of effective adjuvant therapy.
Cyclooxygenases (COXs) are the rate-limiting enzymes
that catalyze the conversion of arachidonic acid to pros-
taglandins (PGs). Two COX isoforms with distinct tissue
distributions and physiological functions have been
identified [3]. COX-1 is constitutively expressed in many
tissues and plays important roles in the control of
homeostasis [4]. Conversely, COX-2 is an inducible
enzyme and is activated by extracellular stimuli such as
growth factors and pro-inflammatory cytokines [5].
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COX-2 is frequently found in many types of cancer,
including colon, lung, breast, pancreas, head and neck
cancers [6-9], and is usually associated with poor prog-
nosis and short survival. Identification of four subtypes
of the PGE receptor (EP1-EP4) has made it possible to
analyze their effects on human cancer cells [10,11]. Stu-
dies have shown that EP1 is coupled to Ca
2+ mobiliza-
tion; EP2 and EP4 activate adenylate cyclase, whereas
EP3 inhibits adenylate cyclase [12-14]. Furthermore,
these studies indicated that cancer cells express multiple
subtypes of the PGE receptor and that each subtype
might be linked to different actions of PGE2.
Tumor invasion and metastasis are the critical steps in
determining the aggressive phenotype of human cancers.
Mortality in cancer patients principally results from
metastatic spread of cancer cells to distant organs [15].
Integrins are a family of transmembrane adhesion recep-
tors comprising 19a and 8b subunits that interact non-
covalently to form up to 24 different heterodimeric
receptors [16]. The combination of different integrin
subunits on the cell surface allows cells to recognize
and respond to a variety of different extracellular matrix
proteins including fibronectin, laminin, collagen and
vitronectin [16]. Activation and elevated expression of
integrin-coupled signaling effectors have been implicated
i nt h ei n d u c t i o no faw i d ev a r i e t yo fh u m a nc a n c e r s ,
including those of the breast, colon, prostate, and ovar-
ies [17-19]. In addition, integrin has also been impli-
cated in metastasis of lung, breast, bladder and colon
cancers [20-22].
The contribution of COX-2 to tumorigenesis has been
intensively studied. Previous studies have shown that
COX-2 modulates cell migration and invasion in several
types of cancer cells [23,24]. Interaction of COX-2 with
its specific EP receptors on the surface of cancer cells has
been reported to induce cancer invasion [25]. However,
the effect of COX-2 and EP receptors on migration activ-
ity in human chondrosarcoma cells is mostly unknown.
Here we found the mRNA expressions of COX-2 and
EP1 receptor in chondrosarcoma patients and chondro-
sarcoma cell lines were significantly higher than in nor-
mal cartilage. COX-2 and PGE2 also increased the
migration and a2b1 integrin up-regulation of human
chondrosarcoma cells. In addition, EP1 receptor, phos-
pholipase Cb3 (PLCb3), protein kinase Ca (PKCa), c-Src
and NF-B signaling pathways were involved.
Results
COX-2 directed migration of chondrosarcoma cells via the
EP1 receptor
COX-2 expression has been reported to stimulate direc-
tional migration and invasion of human cancer cells
[23,24]. We used the IPTG-inducible COX-2 gene
expression vector to examine the role of COX-2 in
chondrosarcoma cells. JJ012 cells were transfected with
IPTG-inducible COX-2 gene expression vector or con-
trol vector, and then IPTG (5 mM) was added for 24 hr.
By Western blot analysis and ELISA, respectively, we
found that IPTG induced COX-2 and PGE2 expression
(Fig. 1A&1B). Furthermore, over-expression of COX-2
enhanced cell migration in chondrsarcoma cells
(Fig. 1C). To confirm IPTG-inducible COX-2-mediated
cell migration, the COX-2 specific inhibitors (celebrex
and NS-398) were used. Celebrex and NS-398 but not
COX-1 specific inhibitor (valeryl salicylate) reduced
IPTG-inducible COX-2-mediated cell migration
(Fig. 1D). We then directly exposed JJ012 cells to PGE2
and examined the migration activity. Stimulation of cells
with PGE2 increased the migration activity in chondro-
sarcoma cells dose-dependently (Fig. 1E). We also exam-
ined human chondrosarcoma tissues for the expression
of the COX-2 using qPCR. Expression of mRNA levels
of COX-2 in human chondrosarcoma tissues (Fig. 1F,
lines 5-8) and chondrosarcoma cell lines (SW1353 and
JJ012) were significantly higher than those in normal
cartilage (Fig. 1F, lines 1-4). Compared with normal car-
tilage, human chondrosarcoma tissues expressed a
higher level of COX-2 mRNA (Table 1). In addition, pri-
mary chondrosarcoma cells and SW1353 or JJ012 cell
lines were more migratory than normal chondrocyte
(Fig. 1G). Thus, expression of COX-2 was associated
with a metastatic phenotype of chondrosarcoma cells.
PGs exert their effects through interaction with speci-
fic EP1-4 subtype receptors [10-14]. To investigate the
role of EP1-4 subtype receptors in COX-2-mediated
increase of cell migration, we assessed the distribution
of these EP subtype receptors in human chondrosar-
coma cells by qPCR analysis. The mRNAs of EP1, EP2,
EP3, and EP4 subtype receptors could be detected in
human chondrosarcoma cells (Fig. 2A). After IPTG/
COX-2-transfected JJ012 cells were treated for 24 hr
with IPTG, the mRNA level of EP1 subtype receptor
was increased, whereas EP2 and EP4 receptor mRNA
remained un-changed (Fig. 2A). In addition, a similar
induction of EP1 receptor mRNA, but not EP2 and EP4
receptor subtypes, was observed in JJ012 cells treated
with PGE2 (Fig. 2B). However, over-expression of COX-
2 and exogenous PGE2 slightly increased expression of
EP3 receptor (Fig. 2A&2B). On the other hand, the
mRNA levels of EP1 receptor in human chondrosar-
coma tissues (Fig. 2C, lines 5-8) and chondrosarcoma
cell lines (SW1353 and JJ012) were significantly higher
than those in normal cartilage (Fig. 2C, lines 1-4). Com-
pared with normal cartilage, human chondrosarcoma
tissues expressed a higher level of EP1 mRNA (Table 1).
To determine the role of EP1 receptor-dependent
signaling in the regulation of cell migration in
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specific agonists, and then the cell migration activity was
examined. Of the agonists tested, only the EP1/EP3-
selective receptor agonist, 17-phenyl trinor PGE2 (3
μM), significantly increased the migration activity (Fig.
2D). In contrast, butaprost (EP2 agonist; 10 μM) and
11-deoxy-PGE1 (EP2/EP4-selective agonist; 10 μM)
failed to up-regulate cell migration. Sulprostone (EP3
agonist; 10 μM) slightly increased cell migration in JJ012
cells (Fig. 2D). In addition, treatment with EP1 receptor
antagonist SC19220 (10 μM) effectively antagonized the
potentiating effect of PGE2 on cell migration activity
(Fig. 2D). To further confirm this stimulation-specific
mediation by EP1 receptor without EP3 receptor con-
tamination, we assessed the role of EP1 and EP3 by
using ON-TARGET smart pool EP1 and EP3, which
Figure 1 COX-2-directed migration of human chondrosarcoma cells. JJ012 cells were transfected with IPTG/COX-2 expression plasmid or
control vector for 24 hr followed by stimulation with IPTG (5 mM) for 24 hr, the COX-2 expression, PGE2 production and migration activity were
determined by Western blot analysis (A), ELISA assay (B) and Transwell (C). JJ012 cells were transfected with IPTG/COX-2 expression plasmid or
control vector for 24 hr, and pretreated with valeryl salicylate (20 μM), celebrex (10 μM) or NS-398 (20 μM) for 30 min followed by stimulation
with IPTG (5 mM), and in vitro migration was measured with the Transwell after 24 hr (D). JJ012 cells were incubated with various concentrations
of PGE2, and in vitro migration activity measured with the Transwell after 24 hr (E). Total RNA were extracted from normal cartilage (lines 1-4),
chondrosarcoma patients (lines 5-8) or from chondrosarcoma cell lines (SW1353 and JJ012), and subjected to qPCR analysis for COX-2 (F). The
migration activity of each cells measured in vitro with the Transwell chamber after 24 h showed a significantly higher migration activity in
primary chondrosarcoma and chondrosarcoma cell lines as compared with primary chondrocyte (G). Results are expressed as the mean ± S.E. *,
p < 0.05 compared with control; #, p < 0.05 compared with PGE2-treated group.
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and pooling [26]. Transfection of cells with ON-TAR-
GET smart pool EP1 and EP3 siRNA reduced EP1 and
EP3 expression, respectively (Fig. 2E; upper panel).
Transfection of cells with EP1 but not EP3 siRNA effec-
tively inhibited the PGE2-mediated migration of chon-
drosarcoma cells (Fig. 2E; lower panel). These results
indicate that PGE2 increased cell migration in human
chondrosarcoma cells via EP1 receptor.
PGE2-directed migration of chondrosarcoma cells involves
a2b1 integrin up-regulation
Previous studies have demonstrated significant expres-
sion of integrins in human chondrosarcoma cells [27].
We therefore, hypothesized that integrins may be
involved in PGE2-directed migration of chondrosarcoma
cells. Flow cytometry analysis showed that PGE2 induced
the cell surface expression of a2a n da2b1i n t e g r i ni n
JJ012 cells (Fig. 3A). To confirm this finding, expression
of mRNAs in the integrins in response to PGE2 was
analyzed by qPCR. Treatment of JJ012 cells with PGE2
induced the mRNA expression of a2a n db1 integrins
(Fig. 3B). In addition, treatment of IPTG/COX-2-trans-
fected cells with IPTG increased mRNA expression of
a2a n db1i n t e g r i n s( F i g .3 C ) .F u r t h e r m o r e ,c o m p a r e d
with normal cartilage, human chondrosarcoma tissues
expressed higher levels of a2a n db1i n t e g r i nm R N A
( T a b l e1 ) .T h e r e f o r e ,t h ea2b1 integrin plays an impor-
tant role in PGE2-induced migration of human chondro-
sarcoma cells. Stimulation of cells with PGE2 also
increased mRNA expression and cell surface expression
of a2a n db1 integrin time-dependently (Fig. 3D&3E).
Pretreatment of cells for 30 min with anti-a2b1 mono-
clonal antibody (mAb) (3 μg/ml) markedly inhibited the
PGE2-induced cell migration (Fig. 3F). On the other
hand, EP1/3 agonist enhanced the cell surface expres-
sion of a2b1 integrin (Fig. 3G). Pretreatment of cells
with SC19220 reduced PGE2-mediated a2b1i n t e g r i n
expression (Fig. 3G). These data suggest that PGE2-
induced cancer migration may occur via activation of
the a2b1 integrin.
The PLC, PKC and c-Src signaling pathway is involved in
PGE2-mediated integrin upregulation and cell migration
of chondrosarcoma cells
It has been reported that PLC/PKC/c-Src dependent
pathway is involved in EP1-mediated bone formation
[28]. We therefore directly measured the phosphorylation
of PLC, PKC and c-Src in response to PGE2. Treatment
of JJ012 cells with PGE2 induced the phosphorylation of
PLCb3, PKCa and c-Src time-dependently (Fig. 4A). In
addition, PKCa activity was also increased by PGE2 treat-
ment of human chondrosarcoma cells time-dependently
(Fig. 4E). Furthermore, pretreatment of cells with PI-PLC
inhibitor (U73122), PKC inhibitor (GF109203X) and
c-Src inhibitor (PP2) reduced PGE2-increased cell migra-
tion and integrin up-regulation (Fig. 4B&4D). Transfec-
tion of cells with PKCa and c-Src mutant or PLCb
siRNA also inhibited PGE2-mediated migration activity
(Fig. 4C). Transfection of cells with PLC siRNA reduced
Table 1 Correlation levels of cyclooxygenase-2 (COX-2), EP1, a2 and b1 integrin expression in human chondrosarcoma
and normal cartilage
Normal cartilage Chondrosarcoma
Patient COX-2 EP1 a2 integrin b1 integrin Patient Grade Location COX-2 EP1 a2 integrin b1 integrin
1 100% 100% 100% 100% 13 II Pelvis 402% 378% 501% 399%
2 81% 127% 95% 99% 14 II Scapular 479% 391% 389% 420%
3 93% 139% 112% 103% 15 II Pelvis 331% 297% 391% 475%
4 112% 81% 98% 75% 16 II Humerus 339% 289% 402% 512%
5 71% 66% 74% 86% 17 II Humerus 597% 661% 505% 612%
6 55% 69% 67% 97% 18 II Scapular 697% 788% 667% 669%
7 61% 55% 85% 92% 19 II Pelvis 711% 791% 719% 739%
8 39% 41% 75% 66% 20 II Pelvis 456% 505% 522% 712%
9 102% 112% 101% 108% 21 II Scapular 421% 571% 565% 705%
10 111% 121% 112% 122% 22 II Pelvis 397% 339% 631% 669%
11 91% 81% 77% 72% 23 II Scapular 338% 397% 668% 612%
12 121% 108% 102% 105% 24 II Pelvis 897% 721% 612% 579%
25 I Pelvis 322% 259% 339% 312%
26 I Pelvis 217% 267% 337% 332%
27 I Humerus 205% 201% 269% 279%
28 I Scapular 272% 288% 307% 309%
29 I Scapular 301% 322% 365% 331%
Results are expressed as % of patient 1
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Page 4 of 14Figure 2 EP1 receptor is involved in PGE2-mediated migration of human chondrosarcoma cells. (A) JJ012 cells were transfected with
IPTG/COX-2 expression plasmid or control vector for 24 hr followed by stimulation with IPTG (5 mM) for 24 hr, the mRNA expression of EP
receptors was determined by qPCR. (B) JJ012 cells were incubated with PGE2 for 24 hr, and the mRNA expression of EP receptors was
determined by qPCR. (C) Total RNA were extracted from normal cartilage (lines 1-4), chondrosarcoma patients (lines 5-8) or from
chondrosarcoma cell lines (SW1353 and JJ012), and subjected to qPCR analysis for EP1 receptor. (D) JJ012 cells were 17-phenyl trinor PGE2
(3 μM), butaprost (10 μM), sulprostone (10 μM), 11-deoxy-PGE1 (10 μM) and PGE2 plus SC19220 (10 μM), and in vitro migration activity measured
with the Transwell after 24 hr. (E) Cells were transfected with EP receptors siRNA for 24 hr followed by stimulation with PGE2, and in vitro
migration measured with the Transwell after 24 hr. Results are expressed as the mean ± S.E. *, p < 0.05 compared with control; #, p < 0.05
compared with PGE2-treated group.
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Page 5 of 14Figure 3 COX-2-directed migration of human chondrosarcoma cells involves up-regulation of a2b1i n t e g r i n . (A) JJ012 cells were
incubated with PGE2 for 24 hr, and the cells surface a5, a2, b3, a5b1, avb3 and a2b1 integrin was determined using flow cytometry. (B) Cells
were incubated with PGE2 for 24 hr, and the mRNA levels of a2 and b1 integrin was determined using qPCR. (C) JJ012 cells were transfected
with IPTG/COX-2 expression plasmid or control vector for 24 hr followed by stimulation with IPTG (5 mM) for 24 hr, the mRNA expression of a2
and b1 integrin was determined by qPCR. JJ012 cells were incubated with PGE2 for indicated time intervals, and mRNA and cell surface a2b1
integrin were examined by qPCR (D) and flow cytometry (E). (F) Cells were pretreated with a2b1 monoclonal antibody (3 μg/ml) for 30 min
followed by stimulation with PGE2. The in vitro migration activity measured after 24 hr. (E) JJ012 cells were treated with 17-phenyl trinor PGE2
(3 μM), 11-deoxy-PGE1 (10 μM), PGE2, and PGE2 plus SC19220 (10 μM), and cells surface a2b1 integrin was determined using flow cytometry.
Results are expressed as the mean ± S.E. *, p < 0.05 compared with control; #, p < 0.05 compared with PGE2-treated group.
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Page 6 of 14Figure 4 PLC/PKC/c-Src signaling pathway is involved in PGE2-mediated migration and inte g r i nu p r e g u l a t i o ni nh u m a n
chondrosarcoma cells. (A) JJ012 cells were incubated with PGE2 for indicated time intervals, and p-PLCb3, p-PKCa and p-c-Src expression was
determined by Western blot analysis. (B&D) JJ012 cells were pretreated for 30 min with U73122, GF109203X or PP2. Then they were followed by
stimulation with PGE2, and in vitro migration and cell surface a2b1 integrin were measured with the Transwell and flow cytometry after 24 hr.
(C) Cells were transfected with PKCa or c-Src mutant and PLCb siRNA for 24 hr followed by stimulation with PGE2, and in vitro migration
measured with the Transwell after 24 hr. JJ012 cells were incubated with PGE2 for indicated time intervals, and PKCa activity was determined by
the PKCa kinase assay kit. Results are expressed as the mean ± S.E. *, p < 0.05 compared with control; #, p < 0.05 compared with PGE2-treated
group
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results, it appears that PGE2 acts through the PLCb,
PKCa and c-Src dependent signaling pathway to enhance
a2b1 integrin expression and cell migration in human
chondrosarcoma cells.
NF-B is involved in PGE2-mediated integrin upregulation
and migration activity
As previously mentioned, NF-B activation is necessary
for the migration and invasion of human chondrosar-
coma cells [27]. To examine whether NF-B activation is
involved in PGE2-induced cancer migration, an NF-B
inhibitor, PDTC, was used. Fig. 5A&5B show that chon-
drosarcoma cells pretreated with PDTC inhibited the
PGE2-induced migration and integrin expression of
chondrosarcoma cells. Furthermore, cells pretreated with
TPCK (3 μM), an IB protease inhibitor, also reduced
PGE2-induced migration of cancer cells (Fig. 5A&5B).
Therefore, the NF-B pathway has a role in PGE2
induced migration of chondrosarcoma cells. We further
examined the upstream molecules involved in PGE2-
induced NF-B activation. Stimulation of cells with PGE2
induced IKKa/b phosphorylation in a time-dependent
manner (Fig. 5C). Furthermore, transfection with IKKa
or IKKb mutant markedly inhibited the PGE2-induced
cell migration (Fig. 5D). These data suggest that IKKa/b
activation is involved in PGE2-induced the migration
activity of human chondrosarcoma cells. Treatment of
chondrosarcoma cells with PGE2 also caused IBa phos-
phorylation in a time-dependent manner (Fig. 5C).
Figure 5 PGE2 induces a2b1 integrin upregulation and cell migration through NF-B activation. Cells were pretreated with PDTC or TPCK
for 30 min, then they were followed by stimulation with PGE2, and in vitro migration (A) and a2b1 integrin expression (B) were measured with
the Transwell and flow cytometry after 24 hr. (C) JJ012 cells were incubated with PGE2 for indicated time intervals, p-IKK, p-IBa and p-p65
expression was determined by Western blot analysis. (D) Cells were transfected with IKKa or IKKb mutant for 24 hr followed by stimulation with
PGE2, and in vitro migration measured with the Transwell after 24 hr. (E) Cells were pretreated with U73122, GF109203X, PP2, PDTC, TPCK, PDTC
for 30 min or co-transfected with PLCb siRNA, PKCa mutant, IKKa mutant, IKKb mutant for 24 hr before incubation with PGE2 for 24 hr. The
NF-B activity was measured. (F) Cells were pretreated with U73122, GF109203X or PP2 for 30 min followed stimulation with PGE2 for 60 min,
and p-p65 expression was examined by Western blot analysis. Results are expressed as the mean ± S.E. *, p < 0.05 compared with control; #,
p < 0.05 compared with PGE2-treated group
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536 phosphorylation
increases NF-B transactivation [29]. Therefore, the anti-
body specific against phosphorylated p65 Ser
536 was
employed to examine p65 phosphorylation. Treatment of
cells with PGE2 for various time intervals resulted in p65
Ser
536 phosphorylation (Fig. 5C). To directly determine
NF-B activation after PGE2 treatment, chondrosarcoma
cells were transiently transfected with B-luciferase as an
indicator of NF-B activation. As shown in Fig 5E, PGE2
treatment of chondrosarcoma cells for 24 hr caused
increase in B-luciferase activity. In addition, U73122,
GF109203X, PP2, PDTC and TPCK or PLCb siRNA,
PKCa,I K K a and IKKb mutant reduced PGE2-mediated
NF-B activity (Fig. 5E). Furthermore, U73122,
GF109203X and PP2 reduced PGE2-mediated p65 phos-
phorylation (Fig. 5F). Taken together, these data suggest
that activation of EP1 receptor, PLC, PKC and c-Src
pathway is required for PGE2-induced NF-B activation
in chondrosarcoma cells.
Discussion
The elucidation of the molecular biology of cancer cells in
recent years has identified various molecular pathways
that are altered in different cancers. This information is
currently being exploited to develop potential therapeutic
targets. To achieve metastasis, cancer cells must evade or
co-opt multiple rules and barriers. Several discrete steps
are discernible in the biological cascade of metastasis: loss
of cellular adhesion, increased motility and invasiveness,
entry and survival in circulation, exit into new tissue, and
eventual colonization of a distant site [30]. The mechan-
ism of metastasis is a complicated and multistage process.
Here, we provide evidence that a2b1i n t e g r i na c t sa sa
crucial transducer of cell signaling, regulating cell migra-
tion and COX-2 act as a critical mediator of the metastatic
activity of cancer cells in the tumor microenvironment. In
addition, a2b1 integrin mAb, U73122, GF109203X, PP2,
PDTC, TPCK, PLC siRNA, PKC mutant, c-Src mutant,
IKKa mutant and IKKb mutant reduced PGE2-mediated
cell migration in SW1353 cells (Additional file 1 - Figure
S1). Furthermore, U73122, GF109203X, PP2, PDTC and
TPCK also abolished PGE2-increased a2b1i n t e g r i n
expression in SW1353 cells (Additional file 2 - Figure S2).
Therefore, the same signaling pathways are involved in all
chondrosarcoma cells. Moreover, a2b1i n t e g r i nm A b ,
U73122, GF109203X, PP2, PDTC, TPCK and EP1 siRNA
reduced PGE2-mediated cell invasion in JJ012 cells [Trans-
well filters were precoated with Matrigel basement mem-
brane matrix (BD Biosciences, Bedford, MA)] (Additional
file 3 - Figure S3). Therefore, the same signaling pathways
are involved in PGE2-mediated cell invasion in human
chondrosarcoma cells.
COX-2 is a pleiotropic enzyme that mediates many
physiological functions such as inhibition of cell
apoptosis, augmentation of angiogenesis, as well as
increased cell motility. These COX-2-mediated functions
are mediated in part by various genes such as B-cell lym-
phoma-2 [31], myeloid cell leukemia-1, VEGF-A [32] and
metalloproteinases [33]. However, the effect of COX-2
on migration activity in human chondrosarcoma cells is
mostly unknown. Using qPCR analysis, we found that the
expression of mRNA levels of COX-2 in human chondro-
sarcoma tissues and chondrosarcoma cell lines were sig-
nificantly higher than those in normal cartilage. In this
study, we used osteoarthritic cartilage to referee normal
cartilage. However, cartilage from osteoarthritic patients
may up-regulation COX-2 compared with normal carti-
lage. Therefore, the expression of COX-2 between
normal cartilage, osteoarthritic cartilage and chondrosar-
coma needs further examination. On the other hand,
most of patient samples were isolated from low grade
chondrosarcoma patients. Notably, grade 1 chondrosarco-
mas are not considered clinically overtly malignant or
even locally aggressive lesion. Therefore, it might be pos-
sible that increased COX-2 expression was a result of
inflammation for metaplasia. The expression of COX-2
in high grade chondrosarcomas are needed further exam-
ination. Moreover, primary chondrosarcoma cells and
SW1353 or JJ012 cell lines were more migratory than
normal chondrocyte. Our data provided the evidence
that the expression of COX-2 is associated with a meta-
static phenotype of chondrosarcoma cells. COX-2 exert it
effects through interaction with specific EP1-4 receptors
[10-14]. However, the expression of EP receptors in
chondrosarcoma cells is largely unknown. We found that
the chondrosarcoma cells expressed EP1-4 receptors.
However, EP1 but not other EP receptors was required
for PGE2-induced migration activity. Treatment with
butaprost (EP2 agonist), and 11-deoxy-PGE1 (EP2/EP4
selective agonist) failed to up-regulate cell migration.
Furthermore, EP1 but not EP3 siRNA inhibited PGE2-
induced cell migration. Therefore, our data suggest a cri-
tical role for EP1 receptor in the PGE2-mediated cell
migration in human chondrosarcoma cells.
Integrins link the extracellular matrix to intracellular
cytoskeletal structures and signaling molecules and are
implicated in the regulation of a number of cellular pro-
cesses, including adhesion, signaling, motility, survival,
gene expression, growth and differentiation [3,34]. Using
flow cytometry analysis, we found that PGE2 increased
a2b1b u tn o ta5, b3, a5b1o ravb3 integrin expression,
which plays an important role during tumor metastasis.
Furthermore, PGE2 also increased the mRNA levels of a2
and b1 integrins. In addition, over-expression COX-2
increased the mRNA expression of a2a n db1i n t e g r i n s .
It has been often reported that a2b1i n t e g r i nh a s
revealed the ability to act as critical molecules as regards
metastasis the ability of chondrosarcoma cells [35]. In
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increased migration activity of chondrosarcoma cells
[35]. Similarly, it was found that elevated expression of
Cyr61 induced gastric cancer cell migration through
a2b1 integrin [36]. Kawashima et al., also reported that
tumour necrosis factor alpha induced migration of osteo-
sarcoma cells via a2b1 integrin [37]. Collectively, our
data also reveal that COX-2 and its downstream effector
integrin a2b1, could constitute a potential target for
future treatment of metastasis of chondrosarcoma cells.
It has been reported that PLC/PKC/c-Src dependent
pathway is involved in EP1 receptor signaling [28]. In
present study, we found PGE2 increased PLCb3p h o s -
phorylation in JJ012 cells. Several isoforms of PKC have
been characterized at the molecular level and these have
been found to mediate several cellular molecular
responses [38]. We demonstrated that PKC inhibitor
GF109203X antagonized the PGE2-mediated potentiation
of migration activity and integrin expression, suggesting
that PKC activation is an obligatory event in PGE2-
induced a2b1 integrin expression in these cells. This was
further confirmed by the result that the dominant nega-
tive mutant of PKCa inhibited the enhancement of
migration activity by PGE2.S r c ,at y r o s i nk i n a s e ,p l a y sa
critical role in the induction of chemokine transcription
[39]. In human aortic endothelial cells, oxidized phos-
pholipids induce IL-8 expression through c-Src activation
[39]. As c-Src has been reported to be a downstream
effector of G protein-coupled receptor [40], we examined
the potential role of c-Src in the signaling pathway of
PGE2-induced cell migration and integrin expression. We
found that treatment of chondrsarcoma cells with PGE2
induced increases in c-Src phosphorylation at Tyr416.
Taken together, our results provide evidence that PGE2
up-regulates cell migration and integrin expression in
human chondrosarcoma cells via the EP1/PLC/PKCa/c-
Src signaling pathway.
Conclusions
The prognosis for patients with chondrosarcoma distant
metastasis is generally considered very poor; hence, pre-
vention of human chondrosarcoma metastasis is very
important. In our study we observed that COX-2
increases the activity of a2b1 integrin via the EP1, PLC,
PKCa,c - S r c ,a n dN F - B-dependent pathway and
enhances migration of human chondrosarcoma cells.
Furthermore, the discovery of COX-2-mediated signal-
ing pathway increases our understanding of the mechan-
ism of human chondrosarcoma metastasis and may help
us to develop more effective therapies in the future.
Taken together, our data suggest that COX2/EP1 inter-
action plays a novel role in regulating chondrosarcoma
cell migration/invasion in a clinical/experimental setting,
and it would also appear to be feasible as a biological
marker to predict the relative likelihood/extent of
metastasis following chondrosarcoma cell migration.
Methods
Materials
Anti-mouse and anti-rabbit IgG-conjugated horseradish
peroxidase, rabbit polyclonal antibodies specific for PLCb,
PKCa,c - S r c ,I K K ,p - I Ba,I Ba,p 6 5a n dt h es i R N A s
against PLCb and control (negative control for experi-
ments using targeted siRNA transfection; each consisted of
a scrambled sequence that would not lead to the specific
degradation of any known cellular mRNA) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Rabbit polyclonal antibody specific for p-IKKa/b,p -
PLCb3, p-PKCa, p-c-Src and p-p65 were purchased from
Cell Signaling and Neuroscience (Danvers, MA). Rabbit
polyclonal antibodies specific for a2, a5, b3, avb3, a5b1
and a2b1 integrin were purchased from Chemicon (Teme-
c u l a ,C A ) .P G E 2, 17-phenyl trinor PGE2, butaprost, sul-
prostone, 11-deoxy-PGE1, SC19220 and rabbit polyclonal
antibody specific for COX-2, EP1 and EP3 were purchased
from Cayman Chemical (Ann Arbor, MI). Valeryl salicy-
late, NS398, U73122, GF109203X, PP2, PDTC, TPCK and
IPTG (isopropyl-b-D-thiogalactopyranoside) were
obtained from Calbiochem (San Diego, CA). Celebrex was
obtained from Pharmacia Co. (Piscataway, NJ). ON-TAR-
GET smart pool EP1 and EP3 siRNA and ON-TARGET
plus siCONTROL Nontargeting pool siRNA were pur-
chased from Dharmacon. The COX-2 IPTG-induced
expression plasmid, p-NLR-COX2 was a gift from Dr. W.
M. Fu (National Taiwan University) [41]. The IKKa(KM)
and IKKb(KM) mutants were gifts from Dr. H. Nakano
(Juntendo University, Tokyo, Japan). The PKCa dominant
negative mutant was a gift from Dr. V. Martin (Louis Pas-
teur de Strasbourg University, France). The c-Src domi-
nant negative mutant was a gift from Dr. S. Parsons
(University of Virginia Health System, Charlottesville, VA).
The NF-B luciferase plasmid was purchased from Strata-
gene (La Jolla, CA) and luciferase assay kit was purchased
from Promega (Madison, MA, USA). All other chemicals
were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Cell culture
The human chondrosarcoma cell line (JJ012) was kindly
provided by the laboratory of Dr. Sean P Scully (Univer-
sity of Miami School of Medicine, Miami, FL, USA).
The JJ012 cells were cultured in DMEM/a-MEM sup-
plemented with 10% fetal bovine serum (FBS) and main-
tained at 37°C in a humidified atmosphere of 5% CO2.
The human chondrosarcoma cell line (SW1353) was
obtained from the American Type Culture Collection.
The cells were cultured in DMEM/a-MEM supplemen-
ted with 10% FBS and maintained at 37°C in a humidi-
fied atmosphere of 5% CO2.
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The migration assay was performed using Transwell
(Costar, NY; pore size, 8-μm) in 24-well dishes. Before
the migration assay was performed, cells were pretreated
for 30 min with different concentrations of inhibitors,
including the U73122, GF109203X, PP2, PDTC, TPCK
or vehicle control (0.1% DMSO). Approximately 1×10
4
cells in 100 μl of serum-free medium were placed in the
upper chamber, and 300 μl of the same medium con-
taining PGE2 was placed in the lower chamber. The
plates were incubated for 24 h at 37°C in 5% CO2, then
cells were fixed in methanol for 15 min and stained
with 0.05% crystal violet in PBS for 15 min. Cells on the
upper side of the filters were removed with cotton-
tipped swabs, and the filters were washed with PBS.
Cells on the underside of the filters were examined and
counted under a microscope. Each clone was plated in
triplicate in each experiment, and each experiment was
repeated at least three times. The number of migrating
cells in each experiment was adjusted by the cell viabi-
lity assay to correct for proliferation effects of the PGE2
treatment (corrected migrating cell number = counted
migrating cell number/percentage of viable cells) [42].
Flow Cytometric Analysis
Human chondrosarcoma cells were plated in six-well
dishes. The cells were then washed with PBS and
detached with trypsin at 37°C. Cells were fixed for 10
min in PBS containing 1% paraformaldehyde. After rin-
sing in PBS, the cells were incubated with rabbit anti-
human antibody against a2, a5, b3, avb3, a5b1o ra2b1
integrin (1:100) for 1 h at 4°C. Cells were then washed
again and incubated with fluorescein isothiocyanate-con-
jugated goat anti-rabbit secondary IgG (1:150; Leinco
Tec. Inc., St. Louis, MO, USA) for 45 min and analyzed
by flow cytometry using FACS Calibur and CellQuest
software (BD Biosciences, Palo Alto, CA, USA).
Western blot analysis
The cellular lysates were prepared as described pre-
v i o u s l y[ 4 3 ] .P r o t e i n sw e r er e s o l v e do nS D S - P A G Ea n d
transferred to Immobilon polyvinyldifluoride (PVDF)
membranes. The blots were blocked with 4% BSA for 1
hr at room temperature and then probed with rabbit
anti-human antibodies against p-PLCb3, p-PKCa,p - c -
Src or p-p65 (1:1000) for 1 hr at room temperature.
After three washes, the blots were subsequently incu-
bated with a donkey anti-rabbit peroxidase-conjugated
secondary antibody (1:1000) for 1 hr at room tempera-
ture. The blots were visualized by enhanced chemilumi-
nescence using Kodak X-OMAT LS film (Eastman
Kodak, Rochester, NY, USA).
PKC kinase activity assay
P K Ca c t i v i t yw a sa s s e s s e db yaP K CK i n a s eA c t i v i t y
Assay Kit according to manufacturer’s instructions
(Assay Designs, MI). The PKC activity kit is based on a
solid-phase ELISA that uses a specific synthetic peptide
as a substrate for PKC and a polyclonal antibody that
recognized the phosphorylated form of the substrate.
Reporter assay
The chondrosarcoma cells were transfected with repor-
ter plasmid using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s recommendations.
Twenty-four hours after transfection, the cells were trea-
ted with inhibitors for 30 min, and then PGE2 or vehicle
was added for another 24 hr. Cell extracts were then
prepared, and luciferase and b-galactosidase activities
were measured [42,44].
Quantitative real time PCR
Total RNA was extracted from cancer cells using a TRI-
zol kit (MDBio, Taipei, Taiwan). The reverse transcrip-
tion reaction was performed using 2 μgo ft o t a lR N A
that was reversely transcribed into complementary DNA
using oligo(dT) primer. The quantitative real time PCR
(qPCR) analysis was carried out using a Taqman® one-
step PCR Master Mix (Applied Biosystems, CA, USA).
One hundred ng of total cDNA were added per 25-μl
reaction with sequence-specific primers and Taqman®
probes. Sequences for all target gene primers and probes
were purchased commercially [GAPDH was used as
internal control (Applied Biosystems, CA, USA)]. qPCR
assays were carried out in triplicate with an StepOne-
Plus sequence detection system. The cycling conditions
were 10-min polymerase activation at 95°C followed by
40 cycles at 95 °C for 15 s and 60 °C for 60 s. The
threshold was set above the non-template control back-
ground and within the linear phase of target gene ampli-
fication in order to calculate the cycle number at which
the transcript was detected (denoted CT).
Patients and specimen preparation
Upon approval by the local ethics committee, specimens
of tumor tissue or normal cartilage tissue were obtained
from patients, who had been pathologically diagnosed
with chondrosarcoma or knee osteoarthritis (the articu-
lar cartilage was collected) and had undergone surgical
resection at the China Medical University Hospital. The
chondrosarcoma patient group consisted of 6 females
and 11 males and ranged in age from 22 to 68 years
(mean, 48 years). The histologic grade of chondrosar-
coma was checked. Cytologically, increased cellularity
and cytological atypia are the most important features,
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grade of the chondrosarcoma [45]. Eleven patients were
alive without disease, one was alive with disease, two
died without disease, and three died of causes secondary
to progressive disease. The overall survival estimate at 5
years was 90%. The recurrence rate for patients with
adequate surgical margins was 10%, compared with 75%
for patients with inadequate margins. Tissue specimens
were ground and then sonicated in a TRIzol kit. The
mRNA level was analyzed using qPCR analysis.
For primary cultures from human chondrosarcoma
cells, the samples were cleaned of surrounding fat, con-
nective tissue and blood vessels. Thereafter, tissue sam-
ples were minced into pieces using a razor blade. Minced
samples were transferred into 50 ml Falcon tubes, spun
down at 1000 r.p.m. for 5 min and rinsed twice with
fresh PBS. Digestion was performed with 1 mg collage-
nase II/ml PBS at 37°C for 50 min in a shaking water
bath. Cell suspension was pipetted up and down at least
twice during incubation. After digestion, pure FBS was
added to a minimum concentration of 10% to inactivate
the collagenase, followed by a centrifugation step as
described above. Cells were then cultured in Dulbecco’s
modified Eagle’s medium/a-modified Eagle medium sup-
plemented with 10% FBS and maintained at 37°C in a
humidified atmosphere of 5% CO2 [46].
Primary cultures of human chondrocytes were isolated
from articular cartilage as described previously [47]. The
cells were grown in plastic cell culture dishes in 95% air-
5% CO2 with Dulbecco’s modified Eagle’s medium which
was supplemented with 10% FBS, 2 mM-glutamine, peni-
cillin (100 U/ml) and streptomycin (100 μg/ml).
Statistics
The values given are means ± S.E.M. The significance of
difference between the experimental groups and controls
was assessed by Student’s t test. The difference was con-
sidered significant if the p value was < 0.05.
Additional file 1: PLC/PKC/c-Src and NF-B pathways are involved in
PGE2-mediated cell migration in human chondrosarcoma cells.( A )
SW1353 cells were incubated with various concentrations of PGE2, and in
vitro migration activity measured with the Transwell after 24 hr showed
all supported the cell migration in a dose-dependent way. SW1353 cells
were pretreated for 30 min with U73122, GF109203X, PP2 (B), PDTC,
TPCK (C) and a2b1 integrin mAb (E) followed by stimulation with PGE2,
and in vitro migration was measured with the Transwell after 24 hr.
SW1353 cells were transfection for 24 hr with IKKa, IKKb, PKC and c-Src
mutant or PLC siRNA followed by stimulation with PGE2, and in vitro
migration was measured with the Transwell after 24 hr. Results are
expressed as the mean ± S.E. *, p < 0.05 compared with control; #, p <
0.05 compared with PGE2-treated group
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-43-
S1.DOC]
Additional file 2: PLC/PKC/c-Src and NF-B pathways are involved in
PGE2-mediated integrin up-regulation in human chondrosarcoma
cells. (A) SW1353 cells were incubated with PGE2 for 24 hr, and the cells
surface a5, b3, a5b1, avb3a n da2b1 integrin was determined using
flow cytometry. (B) SW1353 cells were pretreated for 30 min with
U73122, GF109203X, PP2, PDTC and TPCK followed by stimulation with
PGE2, and cells surface a2b1 integrin was determined using flow
cytometry. Results are expressed as the mean ± S.E. *, p < 0.05
compared with control; #, p < 0.05 compared with PGE2-treated group
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-43-
S2.DOC]
Additional file 3: EP1/PLC/PKC/c-Src and NF-B pathways are
involved in PGE2-mediated cell invasion in human chondrosarcoma
cells. JJ012 cells were pretreated for 30 min with a2b1 integrin mAb,
U73122, GF109203X, PP2, PDTC and TPCK or transfection for 24 hr with
EP1 siRNA followed by stimulation with PGE2, and in vitro invasion was
measured with the Transwell [filters were precoated with Matrigel
basement membrane matrix (BD Biosciences, Bedford, MA)) after 24 hr.
Results are expressed as the mean ± S.E. *, p < 0.05 compared with
control; #, p < 0.05 compared with PGE2-treated group
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-43-
S3.DOC]
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